{
    "title": "R42960",
    "content": "The Hatch-Waxman Act of 1984 reformed patent and drug laws to balance innovation and competition in the pharmaceutical industry. Congressional focus has shifted to pharmaceutical patent litigation settlements, as brand-name companies must litigate to enforce their patents against generic competitors. Pharmaceutical companies obtain patents for their products and processes, but enforcement requires litigation in federal courts. This can result in judgments of infringement, blocking generic competition, or judgments that the patent is invalid, allowing generic entry. Settlements in pharmaceutical patent litigation may involve cash payments from brand-name companies to generic firms to prevent challenges to patents or the sale of generic versions. Reverse payment settlements in pharmaceutical patent litigation involve brand-name companies making cash payments to generic firms to prevent challenges to patents or the sale of generic versions. These agreements, also known as \"pay-for-delay\" agreements, have sparked debate among observers regarding their anti-competitive nature and potential violation of antitrust laws. Congress has mandated that parties notify federal antitrust authorities of such settlements since 2003. Reverse payment settlements in pharmaceutical patent litigation involve brand-name companies making cash payments to generic firms to prevent challenges to patents or the sale of generic versions. Congress has mandated that parties notify federal antitrust authorities of such settlements since 2003. The U.S. Supreme Court's decision in Federal Trade Commission v. Actavis, Inc. on June 17, 2013, established that the legality of reverse payment settlements should be evaluated under the \"rule of reason.\" The U.S. Supreme Court's decision in Federal Trade Commission v. Actavis, Inc. on June 17, 2013, established that reverse payment settlements should be evaluated under the \"rule of reason.\" Legislation before the 113th Congress also addresses reverse payment settlements, with bills like the Preserve Access to Affordable Generics Act (S. 214) and the FAIR Generics Act (S. 504) proposing reforms to reduce incentives for generic firms to settle with brand-name companies. The FAIR Generics Act (S. 504) aims to reform the Hatch-Waxman Act to reduce incentives for generic firms to settle with brand-name companies. This legislation has not yet been enacted. The report discusses innovation and competition policy issues related to pharmaceutical patent litigation settlements, including reverse payment settlements and their status under antitrust laws. Inventors must submit patent applications to the USPTO for patent protection. Examiners assess the applications for novelty and nonobviousness. The application must include a detailed description and at least one claim defining the invention. The examiner evaluates patent applications for novelty and nonobviousness based on prior art. If granted, the patent owner gains exclusive rights for 20 years. The owner of a granted patent has the right to exclude others from using the claimed invention in the United States for twenty years. This exclusivity allows inventors to practice their inventions or license them to others, enabling them to recoup their investment. In industries like pharmaceuticals, patents can lead to higher prices but also drive innovation. Patent owners must monitor competitors to ensure their invention is not being used without permission. The introduction of generic competition provides lower-cost substitutes for innovative products. Patent owners must monitor competitors for infringement and may need to litigate in federal courts. While a patent grants proprietary rights, FDA approval is required to distribute pharmaceutical products. Developers must demonstrate safety and efficacy through preclinical and clinical investigations for FDA marketing approval. The FDA evaluates test data submitted in a New Drug Application (NDA) to determine marketing approval for new drugs. Before the Hatch-Waxman Act, generic drug manufacturers had to file their own NDAs. Some could rely on published literature for approval, but not all drugs had this option. Some generic manufacturers had to prove the safety and efficacy of their drugs through additional studies, even if their products were identical to approved pharmaceuticals. Critics argued that the approval process for generic drugs was costly and time-consuming, leading to a lack of generic equivalents for important drugs whose patents had expired. The Hatch-Waxman Act created an expedited pathway for generic drug approval, known as an Abbreviated New Drug Application (ANDA), to address the costly and time-consuming process of obtaining FDA marketing approval for generic drugs. This allowed generic manufacturers to demonstrate bioequivalence to pioneer drugs without extensive clinical data or literature evidence. The Hatch-Waxman Act established the Abbreviated New Drug Application (ANDA) pathway for generic drug approval, allowing manufacturers to show bioequivalence to pioneer drugs without extensive clinical data. ANDAs help generic manufacturers avoid costs and delays associated with full NDA filings and can bring FDA-approved bioequivalent drugs to market after relevant patents expire. Congress also provided patent proprietors with a way to restore lost patent term, with a maximum extension period of five years or a total effective patent term of not more than 14 years. The Hatch-Waxman Act allows for a maximum extension period of five years or a total effective patent term of not more than 14 years to compensate brand-name firms for regulatory delays. This extension period grants limited rights for the approved use of the product. The Hatch-Waxman Act established procedures for resolving patent disputes related to generic drug applications. NDA applicants must list patents that could be infringed by generic drugs in the \"Orange Book.\" Generic drug manufacturers must certify their products with respect to these listed patents. Generic drug manufacturers must engage in a certification procedure with respect to Orange Book-listed patents. There are four certification possibilities: (1) brand-name firm has not filed any patent information, (2) patent has expired, (3) generic company agrees not to market until patent expiration, or (4) patent is invalid. Certifications are termed paragraph I, II, III, and IV. An ANDA certified under paragraphs I or II is approved immediately after meeting regulatory requirements. An ANDA with a paragraph III certification requires waiting for approval until the brand-name drug's patent expires. Filing an ANDA with a paragraph IV certification can lead to patent infringement litigation. The Hatch-Waxman Act encourages challenges to pharmaceutical patents. The Hatch-Waxman Act incentivizes generic pharmaceutical manufacturers to challenge patents by offering a 180-day exclusivity period to the first applicant filing a paragraph IV certification. This provision aims to stimulate patent challenges and potentially lead to higher profits for the first applicant. The Hatch-Waxman Act incentivizes generic manufacturers to challenge patents by offering a 180-day exclusivity period to the first applicant filing a paragraph IV certification. However, a first applicant may lose this exclusivity if certain \"forfeiture events\" occur, such as failure to market the product promptly or all certified patents expiring. The possibility of forfeiture under the Hatch-Waxman Act is to prevent delaying the exclusivity period and encourage prompt marketing of generic drugs. If a generic firm's paragraph IV ANDA results in a patent infringement suit, the court may issue an injunction preventing the marketing of the product until the NDA holder's patents expire. The court may issue an injunction preventing a generic drug company from marketing a product if their paragraph IV ANDA results in a patent infringement suit. The injunction will expire on the same date as the NDA holder's patents. Independent generic companies may amend their ANDAs in response, and if the court rules in favor of the generic firm, they can launch their product once FDA approval is obtained. Pharmaceutical patent litigation can lead to various outcomes, including judgments in favor of either party or other resolutions. The court may issue an injunction preventing a generic drug company from marketing a product if their paragraph IV ANDA results in a patent infringement suit. The injunction will expire on the same date as the NDA holder's patents. Independent generic companies may amend their ANDAs in response, and if the court rules in favor of the generic firm, they can launch their product once FDA approval is obtained. Pharmaceutical patent litigation can lead to various outcomes, including judgments in favor of either party or other resolutions. The approval of an ANDA can result in settlements between the NDA holder and generic applicant, with the generic firm agreeing not to challenge the patent or produce a generic version of the drug in exchange for compensation. Opinions on these settlements' impact on social welfare vary, with some considering them anticompetitive. Some believe reverse payment settlements between NDA holders and ANDA applicants are anticompetitive, while others see them as a way to avoid litigation expenses and achieve timely resolutions. Settlements may prevent generic competition by eliminating the possibility of patent invalidity rulings. Reverse payment settlements in litigation involve an exchange of benefits and obligations between rational actors, as explained by Judge Richard Posner. These settlements promote peaceful dispute resolution, save judicial resources, and prevent uncertain courtroom outcomes. If all settlements are deemed as involving forbidden \"reverse payments,\" patent settlements may cease. Reverse payment settlements in pharmaceutical patent litigation may benefit consumers by allowing for generic competition before the patent expires. The Hatch-Waxman Act's dispute settlement procedures could also encourage the use of such settlements. The Hatch-Waxman Act's dispute settlement procedures may promote the use of reverse payment settlements in pharmaceutical patent litigation, altering the traditional balance of risks between patentees and infringers. This Act grants generic manufacturers standing to challenge patent validity through an artificial act of infringement. The Hatch-Waxman Act's dispute settlement procedures have led to the emergence of reverse payment settlements in pharmaceutical patent litigation, shifting the risk balance between patentees and infringers. Generic manufacturers can challenge patent validity without facing the risk of infringing commercial sales, while patent holders face the risk of losing their patent without the potential for infringement damages. This unique aspect of the Act has resulted in the phenomenon of reverse payment settlements. The Hatch-Waxman Act has led to reverse payment settlements in pharmaceutical patent litigation, where patent holders risk losing their patent without infringement damages. Congressional action on these settlements has been limited, with the 2003 Medicare Prescription Drug Act mandating the DOJ and FTC to receive copies of certain patent settlement agreements. The Hatch-Waxman Act has led to reverse payment settlements in pharmaceutical patent litigation. Congressional action on these settlements has been limited, with the 2003 Medicare Prescription Drug Act mandating the DOJ and FTC to receive copies of certain patent settlement agreements. Agreements related to the manufacture, marketing, or sale of brand-name or generic drugs trigger a notification requirement, except for specific types of agreements like purchase orders or employment contracts. The FTC received 140 final resolutions of patent disputes in FY2012. The Hatch-Waxman Act has led to reverse payment settlements in pharmaceutical patent litigation. The FTC received 140 final resolutions of patent disputes in FY2012, with 40 settlements possibly involving pay-for-delay payments. Various courts applied antitrust laws to resolve claims of reverse payment settlements, leading to varying results. The courts applied antitrust laws to address claims of reverse payment settlements in pharmaceutical patent litigation. Different courts reached varying results based on different factual patterns. The primary legal mechanism for addressing anti-competitive conduct, including reverse payment settlements, consists of the Sherman Act, the Clayton Act, the Federal Trade Commission Act, and other federal and state statutes. The Sherman Act prohibits anticompetitive economic conduct, specifically declaring illegal any contract or conspiracy that restrains trade. The courts use the \"rule of reason\" to determine if a practice imposes an unreasonable restraint on competition, considering various factors. The \"rule of reason\" is used by courts to assess if a practice unreasonably restrains competition by balancing anticompetitive consequences against business justifications. Some restraints are deemed unlawful per se if experience shows they harm competition without redeeming qualities. The Supreme Court has established that certain agreements or practices are presumed illegal without detailed inquiry due to their harmful effects on competition. Practices like price fixing, group boycotts, and market division are considered per se violations. Courts may also use a \"quick look\" approach between per se illegality and the rule of reason, where defendants must show pro-competitive justifications to avoid antitrust liability. The plaintiff shows that the defendant engaged in practices similar to those previously deemed per se violations. The defendant must prove pro-competitive justifications to avoid antitrust liability. Appellate courts have varied in their approaches to reverse payment settlements in pharmaceutical patent litigation. The Sixth Circuit held a reverse payment settlement between Hoescht Marion Roussel Inc. and Andrx Pharmaceuticals as per se invalid. The Court of Appeals deemed a reverse payment settlement agreement between Hoescht Marion Roussel Inc. and Andrx Pharmaceuticals as per se invalid, classifying it as a horizontal agreement, a restraint of trade at the same level of competition. However, subsequent Courts of Appeals ruled differently, allowing such settlements as long as they stay within the scope of the patent. One case involved agreements between Abbott Laboratories and generic firms Zenith Goldline Pharmaceuticals and Geneva Pharmaceuticals. Reverse payment settlements are permitted as long as they do not exceed the scope of the patent. In Valley Drug Co. v. Geneva Pharmaceuticals, agreements between Abbott Laboratories and generic firms were initially deemed per se illegal, but the Eleventh Circuit reversed this decision. The Court of Appeals adopted a \"scope of the patent\" approach, allowing antitrust scrutiny only for portions of the agreement that go beyond patent protections. The Court of Appeals for the Third Circuit rejected the \"scope of the patent\" approach for reverse payment settlements, stating that it restricts antitrust law and goes against the policies of the Hatch-Waxman Act and Supreme Court precedent on patent litigation and competition. The Third Circuit rejected the \"scope of the patent\" test for reverse payment settlements, stating it restricts antitrust law and goes against the policies of the Hatch-Waxman Act and Supreme Court precedent on patent litigation and competition. The court emphasized that the presumption of validity for granted patents is procedural, not a substantive right, and that private settlements should not override congressional goals of invalidating weak patents through litigation. This test hinders antitrust authorities from reviewing agreements involving narrow patents. The Third Circuit rejected the \"scope of the patent\" test for reverse payment settlements, stating it restricts antitrust law and goes against the policies of the Hatch-Waxman Act and Supreme Court precedent on patent litigation and competition. The court adopted a \"quick rule of reason\" test that presumed reverse payments were anticompetitive, but parties could rebut by showing pro-competitive benefits. The Supreme Court held that reverse payment settlements should be evaluated under the \"rule of reason\" approach. The Supreme Court agreed to hear the case of Federal Trade Commission v. Actavis, Inc, where they held that reverse payment settlements should be evaluated under the \"rule of reason\" approach. The Court did not find such settlements presumptively illegal under a \"quick look\" analysis. Solvay Pharmaceuticals, the NDA holder of ANDROGEL\u00ae, settled with generic firms Actavis and Paddock Laboratories, who received money in exchange for delaying the marketing of their products before Solvay's patent expired. The FTC charged the parties with violating the Federal Trade Commission Act by unlawfully sharing in Solvay's monopoly profits. The FTC charged Solvay Pharmaceuticals and generic firms Actavis and Paddock Laboratories with violating antitrust laws by agreeing to delay the marketing of generic products in exchange for sharing in Solvay's monopoly profits. The Eleventh Circuit Court of Appeals initially rejected the FTC's claims, citing the \"scope of the patent\" standard, but the Supreme Court later reversed this decision in a 5-3 ruling. The Supreme Court reversed the Eleventh Circuit's decision regarding a reverse payment settlement between Solvay and generic firms, ruling that anticompetitive effects within the scope of a patent do not immunize the agreement from antitrust scrutiny. This decision highlights that patent holders may not be exempt from antitrust liability when enforcing exclusionary rights in cases involving patent invalidity or noninfringement. Enforcing exclusionary rights under the Hatch-Waxman Act involves patent validity or noninfringement assertions. If a generic firm succeeds, the patent holder loses the right to exclude the generic product. Justice Breyer emphasized the need to consider antitrust policies in addition to patent law when assessing settlement agreements. The Court's precedent shows that patent-related settlements can violate antitrust laws by restricting competition. The Court emphasized the need to consider antitrust policies in patent-related settlements, focusing on factors like anticompetitive effects, market power, and procompetitive aspects of the Hatch-Waxman Act. Reverse payment settlements are subject to antitrust scrutiny, despite the judicial policy favoring dispute resolution. The Supreme Court highlighted the importance of antitrust policies in patent settlements, particularly regarding reverse payment settlements. Justice Breyer outlined five considerations supporting subjecting such settlements to antitrust scrutiny, emphasizing the risk of anticompetitive effects and the potential for parties to settle disputes without using reverse payments. The Supreme Court emphasized the need for antitrust scrutiny in patent settlements, focusing on reverse payment settlements. Justice Breyer highlighted the risks of anticompetitive effects and the possibility of resolving disputes without reverse payments. The Court rejected the idea of near-automatic antitrust immunity for reverse payment settlements and declined to adopt a presumptively unlawful approach, instead favoring a case-by-case analysis. The Supreme Court rejected the idea of near-automatic antitrust immunity for reverse payment settlements and emphasized the need for antitrust scrutiny in patent settlements. The Court concluded that the FTC must establish antitrust liability using the traditional rule of reason analysis, rather than a presumptively unlawful approach. Chief Justice Roberts, along with Justices Scalia and Thomas, dissented, suggesting that a reverse payment settlement violates antitrust law only under specific circumstances. Justice Roberts, along with Justices Scalia and Thomas, dissented in the case of Actavis, arguing that a reverse payment settlement violates antitrust law only under specific circumstances. They expressed concerns that the majority holding could discourage generic firms from challenging patents and weaken patent protection for innovators. The Supreme Court's decision in Actavis does not eliminate the ability to settle pharmaceutical patent litigation under the Hatch-Waxman Act, but parties will need to carefully structure and explain their agreements. Those unwilling to do so may have to litigate their cases to a final conclusion. Lower courts now face the complex task of dealing with existing agreements. Parties in pharmaceutical patent cases must structure agreements carefully to avoid litigation. Lower courts must navigate the complexities of Hatch-Waxman antitrust cases. Justice Breyer believes these cases won't always involve detailed patent examinations, but Chief Justice expresses concerns about patent validity and infringement being central to antitrust disputes. Congress has options to consider, including waiting for further judicial developments post the Actavis decision. One option for Congress is to regulate pharmaceutical patent litigation settlements. The Preserve Access to Affordable Generics Act in the 113th Congress addresses reverse payment settlements, declaring them acts of unfair competition. This bill would presume anticompetitive effects if an ANDA filer receives anything of value and agrees to limit or forego. The Fair and Immediate Release of Generics Act, S. 504, aims to discourage reverse payment settlements in pharmaceutical patent litigation by granting generic firms the right to share regulatory exclusivity if they win. The Fair and Immediate Release of Generics Act, S. 504, aims to discourage reverse payment settlements in pharmaceutical patent litigation by granting generic firms the right to share regulatory exclusivity if they win a patent challenge or are not sued for patent infringement by the brand company. The legislation also requires generic firms to abide by any deferred entry date agreed upon in settlements with brand-name firms, and mandates brand-name firms to make a decision on enforcing their patents within 45 days of being notified of a patent challenge by a generic firm under the Hatch-Waxman Act. The settlement of pharmaceutical patent litigation under the Hatch-Waxman Act is crucial for balancing the development of new medicines by brand-name companies and increasing access to medications by generic firms. These settlements, when in line with antitrust principles, promote medical innovation and ensure the distribution of benefits to consumers."
}